New pill targets triple threat of fatty liver, diabetes, and blood fats
NCT ID NCT05464784
Summary
This study is testing whether an oral medication called MN-001 can reduce liver fat and lower triglyceride levels in people who have non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. About 40 participants will take either the study drug or a placebo pill daily for 24 weeks. The main goals are to see if the drug safely reduces liver fat content and improves blood fat levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jubilee Clinical Research, Inc.
Las Vegas, Nevada, 89106, United States
-
Pinnacle Clinical Research at South Texas Research Institute
Edinburg, Texas, 78539, United States
Conditions
Explore the condition pages connected to this study.